(HealthDay)—A four-month rifapentine-based regimen containing moxifloxacin is noninferior to a standard six-month regimen for treatment of tuberculosis, according to a study published in the May 6 […]
German firm BioNTech said Thursday that patent protection for COVID-19 vaccines is not holding back production or supply of the jabs that it developed with Pfizer.
New research published in Experimental Physiology highlight the possible long term health impacts of COVID-19 on young, relatively healthy adults who were not hospitalized and who […]